CAR-T treatment

Phase 2Cell therapy

FFirst Affiliated Hospital of Zhejiang University

CAR-T treatment is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaRecruiting

Multiple MyelomaPhase 2

Recruiting

Competition

Competitive Landscape

259 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

TALVEY

Johnson & Johnson

Phase 3

22 2

Venclexta

AbbVie

Phase 3

17 3

Keytruda

Merck & Co.

Phase 3

17 4

Opdivo

Bristol-Myers Squibb

Phase 3

11 5

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 6

Elranatamab

Pfizer

Phase 3

26 7

Cytosar

Teva

Phase 3

4 8

BLENREP

GGlaxo Dba Glaxosmithkline

Phase 3

11 9

Sylvant

RRECORDATI GROUP

Phase 3

8 10

Linvoseltamab

Regeneron

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Multiple Myeloma

NCT06581640

Clinical

Trials by Indication[1]

Multiple Myeloma2 trials

Chimeric Antigen Receptor Modified T Cells Targeting BCMA for the Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting·TThe First Affiliated Hospital of Xiamen University·Phase 2·NCT06581640·5 enrolled

B Cell Maturation Antigen（BMCA）-Targeted CAR-T for Refractory/Relapsed Multiple Myeloma

Unknown status·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT03931421·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CAR-T treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CAR-T treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CAR-T treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Zhejiang University

CAR-T treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Multiple Myeloma2 trials

References

Drug Info

Quick Facts

Related News